AUG 13, 2016 08:19 AM PDT

Repurposing NSAIDs to Treat Alzheimer's

WRITTEN BY: Xuan Pham
Perhaps one of the best outcomes for pharmacologists is the discovery that common, pre-existing drugs could treat new conditions. Along this line, scientists have made the first step in showing that common NSAIDs may be repurposed to treat Alzheimer’s disease.

The most common pain relievers may also work for Alzheimer's
 
Physical pain is nearly inevitable during the course of daily living, and NSAIDs are among the most common pain relievers in the world. Formally known as non-steroidal anti-inflammatory drugs, NSAIDs are taken by over 30 million Americans for a variety of conditions, from headaches, to sprains, to ease menstrual cramps.
 
As the name implies, NSAIDs work by blocking the body’s inflammation pathway. And this is the crucial link to Alzheimer’s. "There is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer's disease worse,” explained David Brough, professor at the University of Manchester, and senior author of the study, published in Nature Communications.
 


To test the effect of NSAIDs on memory loss and neurodegeneration associated with Alzheimer’s, Brough and his team relied on a transgenic mouse model of the disease. They treated a group of mice with several clinically approved NSAIDs, such as Flufenamic acid and mefenamic acid – delivered via implanted drug pumps for 1 month.
 
The team then assessed these mice’s ability to perform in memory-related tasks relative to before treatment, and also relative to a control group that received placebo treatments. They found NSAID-treated mice showed drastic improvements in memory, similar to levels observed in control mice.
 
"Our research shows for the first time that mefenamic acid, a simple Non-Steroidal Anti Inflammatory Drug can target an important inflammatory pathway called the NLRP3 inflammasome , which damages brain cells,” said Brough. "Until now, no drug has been available to target this pathway, so we are very excited by this result.”
 
Brough is careful to temper his excitement by reminding us that though these are highly promising results, it’s only the first step. "Much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease,” he said.
 
But, it’s worth noting why researchers get more excited when a pre-existing drug shows promise for a new disease. Simply put, things tend to move much faster when this happens. "Because this drug is already available and the toxicity and pharmacokinetics of the drug is known, the time for it to reach patients should, in theory, be shorter than if we were developing completely new drugs,” Brough explained. This could shave off years of moving a drug through the pipeline to get to the market. Brough estimates the shortcut could be by as much as 15 years, which is fantastic news for everyone.
 
But until then, the team have to conduct their due diligence in showing NSAIDs are effective in Alzheimer’s disease. "We are now preparing applications to perform early phase II trials to determine a proof-of-concept that the molecules have an effect on neuroinflammation in humans," said Brough.

Additional source: University of Manchester via EurekAlert!
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 05, 2018
Cardiology
SEP 05, 2018
Stroke Doubles Risk of Dementia
History or recent stroke can double the risk of dementia....
SEP 06, 2018
Neuroscience
SEP 06, 2018
Can This Brain Implant Reverse Paralysis?
When someone suffers an injury or illness that results in paralysis, the loss is devastating. Whether partial or full, when part of the body doesn’t ...
SEP 24, 2018
Drug Discovery
SEP 24, 2018
Further Challenges in Alzheimer Drug Development
Scientists at Trinity College Dublin performed a large-scale international study involving the treatment of Alzheimer's disease, which was published in...
OCT 04, 2018
Health & Medicine
OCT 04, 2018
Lead Paint Contamination in Military Housing Prompts Investigation
Lead paint is a serious health hazard. The sale of lead paint was banned in the United States in 1978, so homes built before the ban are likely to have at ...
NOV 05, 2018
Neuroscience
NOV 05, 2018
How does Brain's GPS work?
Understanding the brain cells involved in decoding and encoding naviagtional information....
NOV 15, 2018
Drug Discovery
NOV 15, 2018
A Subclass of Anti-Aging Compounds Serves as Alzheimer's Drug Candidates
In a publication in Trends in Pharmacological Sciences, a subclass of anti-aging compounds, called geroneuroprotectors (GNPs), have been identified in rese...
Loading Comments...